New research reveals that GLP-1 receptor agonist medications, commonly prescribed for weight loss and diabetes, may offer unexpected heart protection for people living with both obesity and autoimmune disease. A large analysis of over 26,000 adults found that those taking these medications experienced significantly fewer cardiac emergencies, blood clots, and deaths compared to similar patients not using GLP-1 drugs.

What Are GLP-1 Medications and Why Do They Matter for Autoimmune Patients?

GLP-1 receptor agonists, or GLP-1RAs, are a class of medications originally developed to help people with type 2 diabetes manage blood sugar levels and lose weight. Drugs in this category include semaglutide and tirzepatide. Until now, most research focused on their metabolic benefits. This new study, presented at the American Diabetes Association 2026 Scientific Sessions, is the first to examine how these medications affect people who have both obesity and autoimmune disease.

The combination of obesity and autoimmune disease creates a particularly high-risk situation. Both conditions independently increase the likelihood of heart problems and blood clots. When someone has both, their cardiovascular risk multiplies, making them a population that has historically lacked clear treatment guidance.

"This is a high-risk population, and historically we've had limited data to guide treatment decisions. In this real-world analysis, we found a consistent signal toward fewer serious complications including blood clots and lower mortality among patients treated with GLP-1RA," said Amy Sheer, M.D., M.P.H., an associate professor of medicine and director of the Obesity Medicine Fellowship program at the University of Florida.

Amy Sheer, M.D., M.P.H., Associate Professor of Medicine, University of Florida

What Did the Study Find About Heart Protection?

Researchers reviewed electronic health records from over 26,000 adults treated between 2014 and 2024 through the OneFlorida+ network, which includes healthcare organizations across Florida, Georgia, and Alabama. They compared outcomes for people taking GLP-1RA medications with those who did not.

The findings were striking. Among people with obesity and autoimmune disease, those taking GLP-1RA medications experienced:

• 44% lower risk of death: This represents the most dramatic finding, suggesting GLP-1 medications may fundamentally alter disease trajectory for high-risk patients.
• 31% lower risk of pulmonary embolism: A pulmonary embolism occurs when a blood clot travels to the lungs, a potentially life-threatening condition.
• 17% lower risk of venous thromboembolism: This is a blood clot that forms in a vein, a common complication in people with autoimmune disease.
• 21% fewer emergency department visits: Fewer hospitalizations suggest better overall disease management and stability.
• 13% lower stroke risk: The reduction in stroke risk was more modest than other outcomes.

The study found only a nonsignificant trend toward reduced heart attack risk, meaning that benefit was not clearly demonstrated.

How Do GLP-1 Medications Provide These Benefits Beyond Weight Loss?

Researchers believe GLP-1 medications work through multiple mechanisms beyond simply helping people lose weight. The drugs appear to reduce inflammation throughout the body, a key driver of both autoimmune disease and cardiovascular problems. They also improve glucose control and may have direct protective effects on the heart and blood vessels.

The study included people with diverse autoimmune conditions, grouped by the body systems they affect:

• Gastrointestinal diseases: Inflammatory bowel disease and celiac disease, which affect the digestive system.
• Musculoskeletal diseases: Rheumatoid arthritis and psoriatic arthritis, which attack joints and connective tissue.
• Endocrine diseases: Type 1 diabetes, hyperthyroidism, and hypothyroidism, affecting hormone-producing glands.
• Systemic diseases: Lupus and sarcoidosis, which can affect multiple organ systems.
• Nervous system diseases: Multiple sclerosis and other conditions affecting the brain and nerves.
• Skin diseases: Vitiligo and other autoimmune skin conditions.
• Blood diseases: Immune thrombocytopenia and other blood-related autoimmune disorders.
• Cardiovascular diseases: Endocarditis, myocarditis, and vasculitis affecting the heart and blood vessels.

The fact that benefits appeared across this wide range of autoimmune conditions suggests the medications' protective effects are not specific to one disease but rather work through broader anti-inflammatory mechanisms.

What Do Experts Say About These Findings?

The 44% reduction in all-cause mortality caught the attention of leading obesity medicine specialists. Fatima Cody Stanford, M.D., M.P.H., M.P.A., M.B.A., a physician scientist at Massachusetts General Hospital and Harvard Medical School, emphasized the significance of this finding.

"The 44% reduction in all-cause mortality observed among patients with obesity and co-occurring autoimmune disease is a striking finding that demands our attention. As an obesity medicine physician scientist who regularly cares for patients with complex inflammatory conditions, this study reinforces what many of us have suspected clinically that the benefits of GLP-1 receptor agonists extend well beyond blood sugar control and weight loss and may fundamentally alter the disease trajectory for some of our highest-risk patients," Stanford stated.

Fatima Cody Stanford, M.D., M.P.H., M.P.A., M.B.A., Physician Scientist, Massachusetts General Hospital and Harvard Medical School

Dr. Sheer also highlighted the potential for combining GLP-1 medications with existing autoimmune treatments. "I am excited about the combination of medications for these diseases, pairing medicines with known benefits to treat the autoimmune disease with a GLP-1RA. For people who are overweight or living with obesity and an autoimmune disease, this study offers a hopeful signal that medications already in use today may be beneficial in reducing their risk of cardiovascular disease," she noted.

Dr. Sheer also

What Are the Study's Limitations?

While the findings are promising, researchers acknowledge important limitations. Because the study reviewed existing health records rather than conducting a controlled experiment, it cannot definitively prove that GLP-1 medications caused the improved outcomes. Other factors, such as weight loss itself or improved blood sugar control, may have contributed to the benefits.

Additionally, autoimmune diseases are highly diverse, and this study grouped them broadly. More targeted research examining specific autoimmune conditions may reveal whether benefits vary by disease type. The study population was primarily from Florida, Georgia, and Alabama, so findings may not apply equally to all geographic regions or demographic groups.

What Should Patients With Autoimmune Disease and Obesity Consider?

The study participants had an average age of 55 years, with about 73% women and 53% identifying as non-Hispanic white. Their average body mass index (BMI) was 37, which falls into the obesity category. A BMI of 37 roughly corresponds to 258 pounds for someone who is 5 feet 10 inches tall.

For people living with both obesity and autoimmune disease, these findings suggest a conversation with their healthcare provider about GLP-1 medications may be worthwhile. The research indicates that these drugs, already approved and in use, may offer cardiovascular protection beyond their known weight-loss and blood-sugar benefits. However, individual treatment decisions should always be made in consultation with a doctor who understands the patient's specific autoimmune condition and overall health picture.

Researchers emphasize that more studies are needed to fully understand how GLP-1 medications work in autoimmune disease and to identify which patients benefit most. The current findings represent a promising signal that warrants further investigation and may reshape how clinicians approach treatment for this high-risk population.